BR9809641A - Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto - Google Patents

Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto

Info

Publication number
BR9809641A
BR9809641A BR9809641-9A BR9809641A BR9809641A BR 9809641 A BR9809641 A BR 9809641A BR 9809641 A BR9809641 A BR 9809641A BR 9809641 A BR9809641 A BR 9809641A
Authority
BR
Brazil
Prior art keywords
switch
graft rejection
immune responses
link switch
rejection
Prior art date
Application number
BR9809641-9A
Other languages
English (en)
Inventor
Allan D Kirk
David M Harlan
David Thomas
Michael Kauffman
Linda Burkly
Original Assignee
Biogen Inc
Us Navy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Us Navy filed Critical Biogen Inc
Publication of BR9809641A publication Critical patent/BR9809641A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<B>"USO DE UM INTERRUPTOR DE LIGAçãO CD40:CD154 PARA EVITAR RESPOSTAS IMUNES INADAPTADAS, PARTICULARMENTE REJEIçãO A ENXERTO"<D>. Composições e métodos aqui divulgados capitalizam a descorberta de que a rejeição de um enxerto de tecido pode ser inibida usando um interruptor de ligação CD40:CD154, tanto de modo individual como em combinação com outro modulador de imunidade ou imunossupressor. Uma vantajosa combinação sinergística inclui um interruptor de ligação CD40:CD154 e um interruptor de sinalização CD28. Um interruptor de ligação CD40:CD154 tomado como exemplo, é um anticorpo monoclonal anti-CD154, tal como um anticorpo possuindo as características específicas de ligação de antígeno do anticorpo monoclonal 5c8. Um interruptor de sinalização CD28 tomado como exemplo, é uma proteína de fusão CTLA4-Ig. As composições e métodos divulgados, inesperadamente podem ser usadas para prolongar a sobrevivência de tecido enxertado em um hospedeiro receptor, de modo a reverter uma rejeição aguda de enxerto e também para atenuar as conseq³ências imunológicas quanto à deficiência do tecido enxertado.
BR9809641-9A 1997-05-17 1998-05-15 Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto BR9809641A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4679197P 1997-05-17 1997-05-17
US4938997P 1997-06-11 1997-06-11
US8514598P 1998-05-12 1998-05-12
PCT/US1998/010075 WO1998052606A1 (en) 1997-05-17 1998-05-15 Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection

Publications (1)

Publication Number Publication Date
BR9809641A true BR9809641A (pt) 2000-07-11

Family

ID=27366975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809641-9A BR9809641A (pt) 1997-05-17 1998-05-15 Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto

Country Status (20)

Country Link
US (2) US20020119150A1 (pt)
EP (1) EP0980259A1 (pt)
JP (1) JP2002500648A (pt)
KR (1) KR100575069B1 (pt)
CN (1) CN1202864C (pt)
AU (1) AU735592B2 (pt)
BG (1) BG64841B1 (pt)
BR (1) BR9809641A (pt)
CA (1) CA2291156A1 (pt)
EA (1) EA002549B1 (pt)
EE (1) EE9900528A (pt)
HU (1) HUP0003392A3 (pt)
IL (1) IL132882A0 (pt)
IS (1) IS5247A (pt)
NO (1) NO995617L (pt)
NZ (1) NZ500974A (pt)
PL (1) PL192521B1 (pt)
SK (1) SK156099A3 (pt)
TR (1) TR199902817T2 (pt)
WO (1) WO1998052606A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358435A1 (en) * 1999-01-08 2000-07-13 Stuart J. Knechtle Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
DE60037822D1 (de) * 1999-10-22 2008-03-06 Biogen Idec Inc Verwendung eines cd40:cd154 bindungs-unterbrechers zur behandlung immunologischer komplikationen des auges
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CN1441675A (zh) 2000-05-12 2003-09-10 贝斯以色列护理医疗中心有限公司 免疫抑制组合物及方法
US20020039577A1 (en) * 2000-06-09 2002-04-04 Townsend Robert M. Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
EP1179587A1 (de) * 2000-08-09 2002-02-13 Genethor GmbH Verfahren zur Reduzierung von spezifischen Immunreaktionen
MXPA03002262A (es) * 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
RU2446826C2 (ru) * 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
EP1941908B1 (en) * 2005-10-21 2015-08-19 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for heart disease
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007070856A2 (en) * 2005-12-15 2007-06-21 The Research Foundation Of State University Of New York Method for treating immune dysfunction by regulation of cd40 ligand expression
EP3135298B1 (en) * 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
EP2025346B1 (en) * 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
PE20081635A1 (es) * 2007-01-23 2009-01-07 Chugai Pharmaceutical Co Ltd Agentes para suprimir la reaccion de rechazo cronica
TWI528973B (zh) * 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
ES2932398T3 (es) 2010-05-28 2023-01-18 Chugai Pharmaceutical Co Ltd Potenciador de la respuesta de las células T antitumorales
JP6830437B2 (ja) 2014-12-10 2021-02-17 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 疾患を処置するための遺伝子改変された細胞、組織および臓器
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
PE20180802A1 (es) 2015-08-05 2018-05-09 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
KR20200010294A (ko) 2017-05-24 2020-01-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201095B (en) * 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
US5068323A (en) * 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
WO1994004188A1 (en) * 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
JPH06298654A (ja) * 1993-04-12 1994-10-25 Sumitomo Electric Ind Ltd 抗原特異的免疫抑制剤
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
JP2001508450A (ja) * 1997-01-10 2001-06-26 バイオジェン インコーポレイテッド 抗ｃｄ４０ｌ化合物の治療学的投与の方法

Also Published As

Publication number Publication date
IL132882A0 (en) 2001-03-19
CN1202864C (zh) 2005-05-25
CA2291156A1 (en) 1998-11-26
BG103948A (en) 2000-07-31
HUP0003392A2 (hu) 2001-08-28
JP2002500648A (ja) 2002-01-08
KR100575069B1 (ko) 2006-05-02
PL336994A1 (en) 2000-07-31
AU735592B2 (en) 2001-07-12
EE9900528A (et) 2000-06-15
BG64841B1 (bg) 2006-06-30
US20070244053A1 (en) 2007-10-18
TR199902817T2 (xx) 2000-09-21
SK156099A3 (en) 2000-06-12
WO1998052606A1 (en) 1998-11-26
CN1261284A (zh) 2000-07-26
EA002549B1 (ru) 2002-06-27
HUP0003392A3 (en) 2002-09-30
KR20010012671A (ko) 2001-02-26
IS5247A (is) 1999-11-12
EP0980259A1 (en) 2000-02-23
NZ500974A (en) 2001-06-29
NO995617D0 (no) 1999-11-16
NO995617L (no) 2000-01-17
PL192521B1 (pl) 2006-11-30
EA199901046A1 (ru) 2000-10-30
US20020119150A1 (en) 2002-08-29
AU7494098A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
BR9809641A (pt) Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto
WO1995034320A3 (en) Methods for inhibiting antigen specific t cell responses
IL102639A (en) Compositions for inducing cytotoxic t lymphocyte responses
NZ515992A (en) Use of antibodies against CD20 for the treatment of the graft versus host disease
HK1082210A1 (en) Peptide antagonists of zonulin and their use
DE59007188D1 (de) Sitzmöbel, insbesondere Bürostuhl.
CA2081028A1 (en) Cd2 binding domain of lymphocyte function associated antigen 3
EP0687183A4 (en) SYNERGISTIC COMPOSITION OF A CD4-BASED PROTEIN AND ANTIBODY AGAINST HIV-1, AND METHODS OF USE
ES2102813T3 (es) Composiciones farmaceuticas y dermocosmeticas que contienen calostro equino.
BR9601995A (pt) Plano para assento de poltronas divãs cadeiras ou similares
ATE360032T1 (de) Cystein-reiche rezeptoren-train
NZ244731A (en) Colostrum fraction, its preparation and its use as a cell culture media
ATE250625T1 (de) IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
AU4282997A (en) Evaluation and treatment of patients with progressive immunosupression
HK1025500A1 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
AU4326693A (en) Monoclonal antibodies to glycoprotein p
SE9402880D0 (sv) New peptide derivatives
NO905009D0 (no) Todelt kasse av kunststoff eller lignende, som spesielt inneholder flasker.
Scala et al. Lymphocyte activation gene-3 (LAG-3) expression and IFN-γ production are variably coregulated in different human T lymphocyte subpopulations
Horneff et al. Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug
Naylor et al. Thymosin: cyclic nucleotides and T cell differentiation
AR007020A1 (es) Tratamiento de asma con tnfr-ig
SE9502838L (sv) Stol
NO942539L (no) Caseinmakropeptid, antistoffer rettet mot nevnte peptider og anvendelser derav
DK0959899T3 (da) LO-CD2a-antistof samt dets anvendelse til h mning af T-celleaktivering og -proliferation

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE

Free format text: ALTERADO DE: BIOGEN, INC.

B25D Requested change of name of applicant approved

Owner name: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.